Johnson & Johnson
NYSE:JNJ · New York Stock Exchange
-$4.59 today
Vol 18.74M · Avg 7.71M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:JNJ · Revenue to Net Income
Key Ratios
Analysis
$96.4B of revenue converted into $21.0B of net income for the selected period. Gross margin is 69.1% and net margin is 21.8%, showing how much revenue survives after costs and taxes. EPS is $8.65, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.2B +6.0% | $88.8B +4.3% | $85.2B +6.5% | $80.0B +1.6% | $78.7B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $25.6B -6.7% | $27.5B +3.5% | $26.6B +8.0% | $24.6B +5.1% | $23.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $68.6B +11.7% | $61.4B +4.7% | $58.6B +5.8% | $55.4B +0.1% | $55.3B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 72.8% +3.7pp | 69.1% +0.3pp | 68.8% -0.4pp | 69.3% -1.0pp | 70.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $14.7B -14.9% | $17.2B +14.2% | $15.1B +6.7% | $14.1B -1.0% | $14.3B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $23.7B +7.8% | $22.0B +9.2% | $20.1B -0.7% | $20.2B +0.6% | $20.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $43.0B +9.6% | $39.2B +11.4% | $35.2B +2.4% | $34.4B -0.0% | $34.4B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $7.5B +2.2% | $7.3B -2.0% | $7.5B +7.4% | $7.0B -5.7% | $7.4B | $374.2M | $1.2B | $631.8M |
| EBITDA | $41.1B +65.7% | $24.8B +6.3% | $23.3B -12.3% | $26.6B -0.5% | $26.8B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 43.6% +15.7pp | 27.9% +0.5pp | 27.4% -5.9pp | 33.3% -0.7pp | 34.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $25.6B +15.6% | $22.1B -5.4% | $23.4B +11.4% | $21.0B +0.3% | $20.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 27.2% +2.2pp | 24.9% -2.6pp | 27.5% +1.2pp | 26.3% -0.3pp | 26.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.1B -20.7% | $1.3B +5.6% | $1.3B +157.3% | $490.0M +824.5% | $53.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $971.0M +28.6% | $755.0M -2.2% | $772.0M +179.7% | $276.0M +50.8% | $183.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $7.0B +227.9% | -$5.5B +34.6% | -$8.3B -404.7% | -$1.7B +6.3% | -$1.8B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $32.6B +95.2% | $16.7B +10.8% | $15.1B -22.2% | $19.4B +0.9% | $19.2B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 34.6% +15.8pp | 18.8% +1.1pp | 17.7% -6.5pp | 24.2% -0.2pp | 24.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $5.8B +120.4% | $2.6B +51.0% | $1.7B -41.9% | $3.0B +117.1% | $1.4B | $1.3B | -$1.6B | $745.2M |
| Net Income | $26.8B +90.6% | $14.1B -60.0% | $35.2B +95.9% | $17.9B -14.1% | $20.9B | $4.9B | $4.8B | $4.7B |
| Net Margin | 28.5% +12.6pp | 15.8% -25.4pp | 41.3% +18.9pp | 22.4% -4.1pp | 26.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $11 +88.9% | $6 -57.9% | $14 +103.2% | $7 -13.9% | $8 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $11 +90.5% | $6 -57.8% | $14 +103.9% | $7 -13.8% | $8 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $2.4B +0.9% | $2.4B -5.0% | $2.5B -3.1% | $2.6B -0.6% | $2.6B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $2.4B +0.0% | $2.4B -5.1% | $2.6B -3.9% | $2.7B -0.4% | $2.7B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
AbbVie Inc.
NYSE:ABBV
$382.93B
UnitedHealth Group Incorporated
NYSE:UNH
$366.17B
Merck & Co., Inc.
NYSE:MRK
$282.20B
Novartis AG
NYSE:NVS
$281.84B
AstraZeneca PLC
NYSE:AZN
$271.37B
Novo Nordisk A/S
NYSE:NVO
$191.46B
Amgen Inc.
NASDAQ:AMGN
$180.95B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.72B
Pfizer Inc.
NYSE:PFE
$143.97B
Sanofi
NASDAQ:SNY
$101.57B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does JNJ generate?
Johnson & Johnson (JNJ) reported $94.19B of revenue in fiscal 2025.
Is JNJ profitable?
Johnson & Johnson (JNJ) reported $26.80B of net income, with a net margin of 28.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.